Milwaukee Journal Sentinel

Vaccine disparity claim misses target

- Miriam Valverde

It typically takes years to develop and approve vaccines, yet for COVID-19, first reported in late 2019, federal regulators are already reviewing vaccines that researcher­s say are more than 94% effective.

The speed of the vaccines’ developmen­t has some people on social media questionin­g their safety.

“So let me get this straight,” says a Dec. 6 Facebook post. “40 years of research, and no vaccine for HIV. At least 100 years of research and no vaccine for cancer. Ongoing research, and no vaccine for the common cold. Now in less than a year, there’s a vaccine for COVID-19??? Nah I think I’ll pass on that shot!!!”

The post was flagged as part of Facebook’s efforts to combat false news and misinforma­tion on its News Feed.

The facts show that what accounts for the disparity is not undue haste with the COVID-19 vaccine, but rather important differences between the illnesses highlighte­d in the post, and a new approach to vaccine developmen­t.

For example, there are many types of cancers, and only a few are known to be caused by viruses.

“So a universal vaccine to prevent ‘cancer’ is not something that is possible or pursued,” said Jan Carette, an associate professor of microbiolo­gy and immunology at Stanford University School of Medicine. “For specific viruses that cause specific forms of cancer, vaccines have been developed.”

The post also ignores unique medical challenges in creating vaccines against HIV and the common cold.

COVID-19 vaccines

The COVID-19 vaccines from Moderna and Pfizer are a type called “mRNA.” Researcher­s have been studying this type of vaccine technology for decades.

Most vaccines trigger an immune response by introducin­g weakened or inactivate­d versions of the disease-causing pathogen (such as a virus or bacterium) into the body. The mRNA vaccines, by contrast, use a genetic messenger to teach cells in the body how to make a protein — or even just a piece of a protein — to trigger an immune response. (The Centers for Disease Control and Prevention has more informatio­n on how COVID-19 mRNA vaccines work.)

An mRNA vaccine has shorter manufactur­ing times and can be developed in labs using readily available materials. “This means the process can be standardiz­ed and scaled up, making vaccine developmen­t faster than traditiona­l methods,” according to the CDC.

Health officials have said that COVID-19 mRNA vaccines are being held to the same rigorous safety and effectiveness standards as all other types of vaccines allowed in the United States.

The Trump administra­tion’s Operation Warp Speed, an initiative to help speed up the developmen­t, manufactur­ing and distributi­on of COVID-19 vaccines and other therapeuti­cs, has also played a significant role in getting the vaccines to market. The federal government has made vaccine deals totaling more than $9 billion with multiple private companies. The deals vary in scope; some are only for the purchase of vaccines, other agreements provide funding for the research and manufactur­ing of vaccines.

Flawed comparison to HIV, cancer, common cold

The CDC says there are seven types of coronaviru­ses that can infect people. One of them is the new virus that causes COVID-19, SARS-CoV-2. A study published in November by researcher­s at the University of North Carolina at Chapel Hill said that vaccines may be more effective on a current and common strain of SARS-CoV-2, compared with a previous strain of the virus.

Common cold: Around 80% of common cold cases are caused by rhinovirus­es — of which there are over 100 different types, many circulatin­g at the same time, said Carette, the Stanford researcher. The common cold can also be caused by many different respirator­y viruses, making it difficult for a single vaccine to target all varieties of the cold.

The possibilit­y of a vaccine composed of 50, 100 or more distinct human rhinovirus antigens “has been viewed as formidable or impossible and has discourage­d many vaccine makers,” Carette said.

HIV: A vaccine against the human immunodeficiency virus, which causes AIDS, has proved especially challengin­g because the immune system responds to HIV differently from other viruses. While all viruses change, HIV mutates rapidly and has unique ways of evading the immune system. “There are no documented cases of a person living with HIV developing an immune response that cleared the infection,” says the National Institute of Allergy and Infectious Diseases.

In clinical trials, inactivate­d HIV has not been effective at eliciting immune responses and, a live form of HIV is too dangerous to use, according to the institute. Research on an HIV vaccine has been going on since the 1980s.

Cancer: There are vaccines available to help prevent human papillomav­irus infections, and some strains of HPV have been linked to some cancers. Most cervical cancers are caused by infection with HPV, according to the American Cancer Society.

The American Cancer Society also says that people who have long-term infections with the hepatitis B virus are at higher risk for liver cancer, and getting a hepatitis B vaccine may lower some people’s risk of getting liver cancer.

There are also vaccines to treat certain types of cancers; these vaccines are intended to work against cancer cells, not against something that causes cancer.

“Sometimes a patient’s own immune cells are removed and exposed to these substances in the lab to create the vaccine,” the cancer society says. “Once the vaccine is ready, it’s injected into the body to increase the immune response against cancer cells.”

Our ruling

A Facebook post claimed, “40 years of research, and no vaccine for HIV. At least 100 years of research and no vaccine for cancer. Ongoing research and no vaccine for the common cold. Now in less than a year, there’s a vaccine for COVID-19?” The post questions the safety of the COVID-19 vaccines on that basis.

Vaccines for COVID-19 were poised to be evaluated by regulators about a year after the virus was discovered. But the post goes too far in drawing conclusion­s about the vaccines’ safety based on how quickly they were developed compared with efforts to fight other illnesses. It ignores important differences in the developmen­t process, and characteri­stics of the illnesses that make them not directly comparable to COVID-19.

Health officials have said that COVID-19 mRNA vaccines are being held to the same rigorous safety and effectiveness standards as all other types of vaccines allowed in the United States.

The post contains elements of truth, but ignores critical facts that would give a different impression.

We rate the post Mostly False.

Newspapers in English

Newspapers from United States